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AbsTrACT
Introduction Although deaths due to chronic kidney disease 
(CKD) have doubled over the past two decades, few data exist 
to inform screening strategies for early detection of CKD in 
low-income and middle-income countries.
Methods Using data from three population-based surveys 
in India, we developed a prediction model to identify a target 
population that could benefit from further CKD testing, after an 
initial screening implemented during home health visits. Using 
data from one urban survey (n=8698), we applied stepwise 
logistic regression to test three models: one comprised of 
demographics, self-reported medical history, anthropometry 
and point-of-care (urine dipstick or capillary glucose) tests; 
one with demographics and self-reported medical history 
and one with anthropometry and point-of-care tests. The 
‘gold-standard’ definition of CKD was an estimated glomerular 
filtration rate <60 mL/min/1.73 m2 or urine albumin-to-
creatinine ratio ≥30 mg/g. Models were internally validated 
via bootstrap. The most parsimonious model with comparable 
performance was externally validated on distinct urban 
(n=5365) and rural (n=6173) Indian cohorts.
results A model with age, sex, waist circumference, body 
mass index and urine dipstick had a c-statistic of 0.76 (95% 
CI 0.75 to 0.78) for predicting need for further CKD testing, 
with external validation c-statistics of 0.74 and 0.70 in the 
urban and rural cohorts, respectively. At a probability cut-
point of 0.09, sensitivity was 71% (95% CI 68% to 74%) 
and specificity was 70% (95% CI 69% to 71%). The model 
captured 71% of persons with CKD and 90% of persons at 
highest risk of complications from untreated CKD (ie, CKD 
stage 3A2 and above).
Conclusion A point-of-care CKD screening strategy using 
three simple measures can accurately identify high-risk 
persons who require confirmatory kidney function testing.
InTroduCTIon
Chronic kidney disease (CKD) is emerging as a 
health issue of significance across the globe and 
is one of the top 20 causes of death worldwide.1 
Much of the rise in CKD-attributable deaths 
has occurred in low-income and middle-in-
come countries (LMICs).2 3 Few data exist to 
inform screening strategies for early detection 
and management of CKD in LMICs, where 
risk factors for CKD may differ from those in 
high-income countries.4
Expert groups recommend a targeted, rather 
than a population-wide, screening approach to 
detect persons with CKD,5 6 as multiple studies 
suggest that population-based CKD screening 
is not cost effective.7 8 Targeted screening 
Key questions
What is already known?
 ► Chronic kidney disease (CKD) has become one of the 
leading causes of death worldwide, with low-income 
and middle-income countries (LMICs) disproportion-
ately affected.
 ► Expert groups recommend targeted screening for 
CKD over a population-wide approach, as the latter 
is not cost-effective.
 ► There are scarce data surrounding implementation 
of CKD screening strategies in LMICs.
What are the new findings?
 ► A prediction model for presence of CKD that is built 
on non-invasive measures can detect over 70% of 
persons with CKD in urban India while reducing the 
number of people requiring additional serum and 
urine testing.
 ► Using this screening strategy, the majority of per-
sons at highest risk for CKD complications and pro-
gression can be successfully detected and referred 
for preventive treatment.
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Figure 1 Flowchart of analysis sample from CARRS-II: 
we excluded persons on dialysis and those with missing 
urine or serum creatinine data, as long as the availability of 
one did not already qualify them as having CKD. Thus, we 
included a person meeting criteria for CKD based on an 
available serum creatinine, even if he or she were missing 
urine data to determine urine ACR. Conversely, if a person’s 
serum creatinine did not meet CKD criteria and he or she had 
missing urine data, he or she was excluded. ACR, albumin-
to-creatinine ratio; CARRS-II, Center for cArdiometabolic 
Risk Reduction in South Asia study 2015; CKD, chronic 
kidney disease.
Key questions
What do the new findings imply?
 ► By allowing early detection and management, this straightforward 
CKD screening strategy could potentially reduce the number of peo-
ple in resource-limited settings who progress to require costly renal 
replacement therapy.
 ► Implementation of this strategy within pre-existing community out-
reach programmes in LMICs could facilitate appropriate medical 
referrals and eliminate the need for restructuring of primary health-
care delivery in these settings.
strategies developed for LMICs must be implemented 
in settings where primary care health services are often 
under-resourced and/or are built within the framework of 
community outreach rather than in-clinic consultations. 
Community health-worker facilitated ‘all comers’ screening 
programmes for diabetes and hypertension have been vari-
ably instituted in parts of India, Brazil and Uganda,9–11 but 
few CKD screening strategies exist to facilitate appropriate 
referrals for confirmatory testing.12 13
We developed and externally validated a screening 
strategy to identify persons most likely to benefit from 
kidney function testing using three large population-based 
urban and rural cohorts in India. Our goal was to effi-
ciently identify individuals at highest risk for CKD and to 
reduce the pool of people requiring referral to primary 
or secondary health systems for CKD testing, while still 
allowing early detection and management of CKD.
MeTHods
study population
We used cross-sectional survey data from three separate 
cohorts to develop and externally validate a risk prediction 
equation to identify persons for referral for CKD testing. 
We obtained data from three distinct cohorts of adults. Two 
(urban) cohorts are representative of Delhi and Chennai, 
from 2010 to 2012 (Center for cArdiometabolic Risk Reduc-
tion in South Asia study, CARRS-I) and 2015 (CARRS-II). 
The design and methodology of the original CARRS study is 
described in detail elsewhere.14 Both CARRS cohorts consist 
of urban residents by design. The third cohort was derived 
from rural sites within UDAY, a population-based interven-
tion study for diabetes and hypertension with a pre-post 
evaluation design.15 We established a development sample 
of persons at risk for CKD using cross-sectional CARRS-II 
data from Delhi and Chennai. The model developed in 
CARRS-II was externally validated in both Delhi CARRS-I 
data (urban validation set) and UDAY (rural validation 
set). The CARRS and UDAY studies received approval for 
human subjects research from the Ethics Committees of 
the Public Health Foundation of India; the CARRS studies 
were additionally reviewed at All India Institute of Medical 
Sciences (Delhi), Madras Diabetes Research Foundation 
(Chennai) and Emory University.
For all three datasets, we excluded persons missing both 
serum creatinine and urine albumin-to-creatinine ratio 
(ACR) data, as we used these measurements to create a gold 
standard definition of CKD (figure 1, CARRS-II).16 In addi-
tion, we excluded persons who were missing either serum 
creatinine or ACR, as long as the availability of one did 
not already qualify them as having CKD. We hypothesised 
that urine dipstick results would be important correlates 
of CKD risk, and in CARRS-I, this testing was performed 
solely in Delhi. We thus obtained a final sample size of 8698 
in CARRS-II (development set), 4065 in Delhi CARRS-I 
(urban validation set, online supplementary figure 1A) and 
4940 in UDAY (rural validation set, online supplementary 
figure 1B).
definition of CKd
In our ‘gold standard’ definition of CKD, a person 
was classified as having CKD if they had either of the 
following:16
1. Estimated glomerular filtration rate (eGFR) <60 mL/
min/1.73 m2.
2. ACR ≥30 mg/g.
The CARRS-I, CARRS-II and UDAY studies used an 
IDMS-calibrated kinetic Jaffe method to measure serum 
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Table 1 Characteristics of persons with and without CKD 
in a community-based survey from India (CARRS-II)*
No CKD
n=7751
CKD
n=947
Demographics
Age (years), mean±SD 44 (13) 52 (15)
Age categories
  20 to <45 years 4357 (56) 306 (32)
  45 to <65 2850 (37) 431 (46)
  ≥65 544 (7) 210 (22)
Women 4123 (53) 506 (53)
Education (years), mean±SD 9 (5) 8 (5)
Occupation
  Professional 866 (11) 90 (10)
  Skilled† 1282 (17) 120 (13)
  Semiskilled 1006 (13) 92 (10)
  Unskilled 645 (8) 53 (6)
  Unemployed 3817 (49) 570 (60)
  Missing 135 (2) 22 (2)
Household income
  ≤10 000 3176 (41) 392 (41)
  10 001–20 000 2492 (32) 301 (32)
  20 000–40 000 1232 (16) 163 (17)
  >40 000 726 (9) 74 (8)
  Missing 125 (2) 17 (2)
Cooking fuel
  Electric, gas or solar 7445 (96) 917 (97)
  Charcoal or wood‡ 306 (4) 30 (3)
Drinking water source
  Purified or reverse osmosis 2741 (35) 301(32)
  Private tap 2532 (33) 362 (38)
  Public tap§ 2478 (32) 284 (30)
Vegetarian 275 (29) 1963 (25)
Tobacco use (ever) 1779 (23) 256 (27)
Alcohol use (ever) 1670 (22) 228 (24)
Self-reported medical history
Family history (at <60 years)
  Diabetes 2155 (28) 265 (28)
  High blood pressure 1584 (20) 164 (17)
  Heart disease 420 (5) 46 (5)
Diabetes 1082 (14) 367 (39)
  Microvascular complications¶ 170 (2) 88 (9)
Heart disease 217 (3) 84 (9)
Stroke 59 (1) 23 (2)
Hyperlipidaemia 401 (5) 103 (11)
Hypertension 1167 (15) 373 (39)
Kidney disease 291 (4) 67 (7)
  Stone 283 (97) 48 (72)
Continued
and urine creatinine and an immunoturbidimetric assay 
to measure urine albumin at a central RIQAS certified 
laboratory at Public Health Foundation of India. As 
recommended by the Kidney Disease Improving Global 
Outcomes (KDIGO) guidelines, we used the CKD-EPI 
equation to estimate eGFR.16 We opted not to use the 
modified CKD-EPI equation developed by Jessani et al 
in a Pakistani population,17 as it is not widely adopted 
in clinical practice and has comparable performance in 
persons with an eGFR <90 mL/min/1.73 m2; further, its 
association with outcomes is as yet uncertain.
Potential predictors of prevalent CKd
From the complete set of over 500 covariates available 
in CARRS-II, we selected 30 clinically relevant predictors 
that could be easily assessed during a community health 
worker home visit via self-reported medical history, 
anthropometry and point-of-care laboratory tests (eg, 
urine dipstick and capillary blood glucose). We used 
variables in their continuous form where available (eg, 
systolic blood pressure or fasting blood glucose) and 
categorised variables based on clinically relevant cut-offs 
when appropriate (eg, urine dipstick albumin negative or 
trace and ≥1+).
We prespecified three groups of potential predictors 
to be tested in the modelling: (1) all 30 predictors (ie, 
demographic, self-reported medical history, anthropom-
etry and point-of-care testing), (2) only demographic and 
self-reported medical history (n for predictors=23) and 
(3) only anthropometry and point-of-care testing (n=8). 
While blood glucose is often feasible at the point-of-care, 
its use necessitates fasting and additional supplies; we 
therefore tested Model 3 with and without fasting glucose 
to determine its added utility.
We also examined model performance in detecting 
different stages of CKD: moderately increased albu-
minuria (ie, ACR ≥30 mg/g and ≤300 mg/g), severely 
increased albuminuria (ie, ACR >300 mg/g), reduced 
eGFR <60 mL/min/1.73 m2 without albuminuria and 
both reduced eGFR and albuminuria ≥30 mg/g. These 
stages represent increasing risk for complications from 
untreated CKD, with persons who have both reduced 
eGFR and albuminuria being at ‘very high risk’ for 
complications, including progression to end-stage kidney 
disease.18
statistical analysis
Model development: We fit a logistic regression model 
by starting with the prespecified variable pool shown in 
table 1 for each of the three models, including clinically 
relevant interaction terms. We used a step-down selection 
procedure based on the Akaike information criterion to 
select the final predictors. For all continuous variables, 
we used cubic spline terms with knots placed at fixed 
quantiles of the predictor's marginal distribution.19 Since 
our goal was to establish a ‘high-risk’ pool for referral for 
further blood and urine testing, we identified a predic-
tive probability cut-off that maximised sensitivity while 
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No CKD
n=7751
CKD
n=947
Pain on walking** 3050 (40) 476 (50)
Medications
  NSAIDs 115 (2) 20 (2)
  Proton pump inhibitors 204 (3) 53 (6)
Anthropometry and blood pressure
Quetelet’s BMI (kg/m2) 26 (5) 27 (6)
  Missing 59 (1) 11 (1)
Waist circumference (cm) 87 (13) 92 (13)
  Missing 48 (1) 11 (1)
Systolic blood pressure (mm Hg) 125 (19) 139 (25)
  Missing 33 (1) 7 (1)
Diastolic blood pressure (mm Hg) 80 (11) 85 (14)
  Missing 33 (1) 7 (1)
Point-of-care laboratory tests
Urine dipstick glucose
  Trace or nil 7051 (91) 693 (73)
  ≥1+ 576 (7) 222 (23)
  Missing 124 (2) 32 (3)
Urine dipstick protein
  Trace or nil 7640 (99) 834 (88)
  ≥1+ 10 (1) 87 (9)
  Missing 101 (1) 26 (3)
Fasting plasma glucose (mg/dL) 108 (39) 144 (75)
  Missing 1 (0.01) 2 (0.01)
*Numbers represented as N (%) unless otherwise specified.
†Skill categories: skilled (small business owner, small land 
farmer, machinist, truck driver), semiskilled (rickshaw driver, 
carpenter or army infantry), unskilled (landless labourer).
‡Other fuel represents all non-induction fuel including dung, 
charcoal, kerosene.
§Public tap includes public and ‘other’ sources.
¶End-organ complication includes foot ulcers, amputation and 
retinopathy.
**Interpreted as a potential indicator for peripheral vascular 
disease.
CARRS-II, Center for cArdiometabolic Risk Reduction in 
South Asia study 2015; CKD, chronic kidney disease; NSAIDs, 
Nonsteroidal anti-inflammatory drugs.
Table 1 Continued
minimising false positives. We therefore compared model 
predictive ability across probability cut-offs in which the 
sum of sensitivity and specificity was maximised (Youden 
index) but with the restriction that sensitivity was always 
greater than specificity.20 We checked the model discrim-
ination ability by calculating the concordance statistic 
(c-statistic) and checked model calibration by plotting 
the calibration slope.
Model validation: We internally validated Models 1 
through 3 using bootstrap. The bootstrap procedure is 
used to perform internal validation of each predictive 
model and involves taking multiple samples (of the same 
size) from the original data with replacement. These 
samples are used to compute a measure of optimism that 
is an estimate of the bias due to overfitting. The model 
performance index such as the concordance, or c-sta-
tistic, that is computed from the model developed on 
the original data can then be adjusted by subtracting this 
optimism to provide a validated index.19 21 This method 
validates the entire process, including variable selection, 
but as opposed to cross-validation, another method of 
internal validation, it uses the full data set for model 
development.19 Given that this internal validation process 
is based on the original data and not on a completely 
different dataset, the computed statistics will be more 
optimistic of model performance than those derived 
from external validation with a different dataset. Thus, 
we also performed external validation using two other 
datasets.
To identify a model for external validation, we chose 
models with the best discrimination ability and cali-
bration slope (a calibration slope significantly below 1 
reflects substantial model overfitting). If models’ internal 
validation results were comparable, we selected the most 
parsimonious model for external validation using the 
Delhi CARRS-I and rural UDAY analytic samples. In 
sensitivity analyses, we used Random Forest as an alterna-
tive to logistic regression. We used SAS V.9.4 (SAS Insti-
tute, Cary, North Carolina) and R (V.3.5.1), particularly 
R package rms (V.51–2) and boot to perform statistical 
analyses.22–26
Patient and public involvement
Patients and the public were not involved in the design, 
conduct or reporting of this study.
resulTs
The unadjusted prevalence of CKD in the CARRS-II 
development set was 11%. Moderately increased albu-
minuria (ie, ACR ≥30 mg/g and ≤300 mg/g) was most 
common (69% of those with CKD), followed by reduced 
eGFR <60 mL/min/1.73 m2 without albuminuria (11%), 
severely increased albuminuria (ie, ACR >300 mg/g) 
(11%) and both reduced eGFR and albuminuria 
≥30 mg/g (8%).
Table 1 describes persons with and without CKD in 
the CARRS-II development set. Persons with CKD were 
older, had attained fewer years of education, were more 
likely to be unemployed and were more likely to report 
alcohol or tobacco use. Further, they were substantially 
more likely to report a diagnosis of several chronic 
diseases, including diabetes, high blood pressure, stroke, 
peripheral vascular disease and heart disease (76% with 
at least one of the queried chronic diseases in persons 
with CKD vs 53% in persons without CKD). Anthropom-
etry revealed higher Quetelet’s body mass index, waist 
circumference and blood pressure in persons with CKD. 
Of persons with CKD, 9% and 23% had urine dipsticks 
positive for protein and glucose, respectively.
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Table 2 Logistic regression models to predict prevalent CKD
Model 1 Model 2 Model 3a Model 3b
Selected variables* Age
Years of education
Occupation
Tobacco use (ever)
Family history of HTN
DM†
Heart disease†
Stroke†
HTN†
Kidney disease†
Kidney stone†
PAD†
BMI
Waist circumference
BMI × Waist 
circumference
SBP
DBP
Urine dipstick glucose
Urine dipstick albumin
Fasting plasma glucose
Age
Years of education
Source of drinking 
water
Alcohol use
DM†
HTN†
Kidney disease†
Kidney stone†
DM†
Age
Sex
BMI
Waist circumference
BMI × Waist 
circumference
SBP
DBP
Urine dipstick glucose
Urine dipstick albumin
Age
Sex
BMI
SBP
DBP
Urine dipstick albumin
Fasting plasma glucose
C-statistic‡     
  Development 0.79 (0.78 to 0.81) 0.73 (0.72 to 0.75) 0.77 (0.75 to 0.79) 0.77 (0.76 to 0.79)
  Bootstrap validation 0.78 (0.77 to 0.80) 0.73 (0.72 to 0.75) 0.76 (0.75 to 0.78) 0.77 (0.75 to 0.79)
  CARRS I validation – – 0.74 (0.73 to 0.74) –
  UDAY validation – – 0.70 (0.69 to 0.71) –
Calibration slope 0.96 0.98 0.98 0.99
Probability threshold 0.09 0.09 0.09 0.09
  Sensitivity‡ 0.72 (0.69 to 0.75) 0.68 (0.65 to 0.71) 0.71 (0.68 to 0.74) 0.71 (0.68 to 0.74)
  Specificity‡ 0.72 (0.71 to 0.73) 0.67 (0.66 to 0.68) 0.70 (0.69 to 0.71) 0.70 (0.69 to 0.71)
  Positive predictive value‡ 0.24 (0.22 to 0.26) 0.20 (0.19 to 0.21) 0.22 (0.21 to 0.24) 0.22 (0.21 to 0.24)
  Negative predictive value‡ 0.96 (0.95 to 0.96) 0.95 (0.94 to 0.95) 0.95 (0.95 to 0.96) 0.95 (0.95 to 0.96)
*Variables selected from group of variables presented in table 1.
†Self-reported.
‡95% CI.
BMI, body mass index; CKD, chronic kidney disease; DBP, diastolic blood pressure; DM, diabetes mellitus; HTN, hypertension; PAD, 
peripheral arterial disease;SBP, systolic blood pressure.
Model performance in the development cohort
Step-down selection resulted in 20 correlates for Model 
1, including an interaction term between Quetelet’s body 
mass index and waist circumference. Model 1 had an 
internally validated c-statistic of 0.78 and a calibration 
slope of 0.96 (table 2). Relying only on self-reported meas-
ures (Model 2) resulted in the lowest validated c-statistic 
(0.73). Model 3—which relied only on measured varia-
bles—had comparable performance with and without 
fasting plasma glucose (sensitivity 71%, 95% CI 68% to 
74% and validated c-statistic 0.76 for Model 3a; sensitivity 
71%, 95% CI 68% to 74% and validated c-statistic 0.77 for 
Model 3b). The models developed via Random Forest 
performed similarly (online supplementary table 1).
Figure 2 shows the percentage of true CKD cases that 
could be detected (ie, sensitivity) along with the percentage 
of screened persons referred for further kidney function 
testing at different probability thresholds for Model 3a. 
When using a threshold that maximises sensitivity and 
minimises number needed to test (threshold 0.09), the 
model would refer 35% of screened persons for further 
kidney function testing, resulting in 71% of true CKD 
cases being captured within the referred population.
When applied to the CARRS-II development set, our 
model missed more persons with CKD who were: age <45 
than persons with age >65 (61% vs 0%), unskilled than 
were professional (38% vs 27%) and who self-reported 
kidney stone than had diabetes or hypertension (48% vs 
9% and 14%, respectively) (online supplementary table 
2). Overall and across the strata, the model was more 
likely to miss persons with albuminuria alone compared 
with persons who had eGFR <60 mL/min/1.73 m2 and 
albuminuria (ie, KDIGO CKD stage 3A2 or above) (35% 
vs 10%). Figure 3 describes the CKD stages in the urban 
and rural datasets, in persons with CKD and those not 
captured by the model application; in both settings, 
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Figure 2 Percentage of true CKD cases detected (sensitivity) and overall percentage of screened population referred for 
further CKD testing with Model 3a: the optimal threshold for maximisation of sensitivity and specificity, where sensitivity 
exceeded specificity, was at 0.09 (vertical grey line). At this probability threshold using Model 3a, 35% of the screened 
population would be referred to a clinic for serum creatinine and urine albumin-to-creatinine ratio testing, where we expect 
to detect 71% of true CKD cases. Selecting a different probability threshold would result in a different number of persons 
requiring referral and a different sensitivity. Policy makers could chose the optimal threshold based on capacity for screening 
and desired sensitivity. CKD, chronic kidney disease.
persons with KDIGO CKD stage 3A2 or above were least 
likely to be missed.
Model performance in the external validation cohorts
Since Model 3 without fasting plasma glucose (Model 
3a) was the most parsimonious and required the least 
amount of individual measurements, we selected this 
model for external validation. The validation c-statistics 
in the urban CARRS-I and rural UDAY datasets were 0.74 
and 0.70, respectively (table 2).
dIsCussIon
Early detection of CKD that enables intensive clinical 
management to delay its progression relies on develop-
ment of appropriate screening strategies that account 
for region-specific risk factor profiles. To create a model 
for such an approach, we used population-based data 
from India and found that measurement of three clinical 
parameters (body mass index, waist circumference and 
blood pressure) and point-of-care urine dipstick testing 
could identify persons to refer for confirmatory kidney 
disease testing. With 71% sensitivity and 95% negative 
predictive value, application of our model would reduce 
numbers of people needing CKD testing in comparison 
with an ‘all-comers’ approach. Thus, if incorporated 
within a community health worker-led screening strategy 
for other chronic diseases, this ‘two-step’ strategy could 
be an effective, feasible method for integrating CKD 
screening.
No consistent consensus exists in high-resource 
settings regarding screening recommendations for CKD. 
For example, the US Preventive Services Task Force does 
not state a clear position for or against population-based 
CKD screening, citing insufficient evidence,27 and the 
American College of Physicians recommends against 
screening asymptomatic adults.6 On the other hand, 
both Australian College of General Practitioners and 
UK National Institute for Health and Care Excellence 
recommend screening patients with a broad range of 
risk factors, including diabetes, hypertension, acute 
kidney injury, cardiovascular disease, or prostatic hyper-
trophy.28 29 Nephrology expert groups, such as KDIGO, 
encourage a similar approach, identifying persons 
with cardiovascular disease, diabetes and/or hyperten-
sion as high priority for screening and recommending 
consideration of persons who are older, have metabolic 
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Figure 3 Stages of CKD with model false negatives (%) in the urban and rural cohorts. The total bar height reflects the 
number of true CKD cases in each group. The percentage of model FN is shown in light grey. χ² p<0.001 for within-cohort 
differences in FN proportions across CKD stages. There was no significant difference in the proportions of model FN across 
cohorts. Alb, albuminuria; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; FN, false negatives.
syndrome, or have a history of tobacco use.30 Implemen-
tation of this latter, targeted-screening strategy assumes 
regular interaction with a primary care system and its 
success hinges on careful ascertainment of a broad range 
of risk factors with a reliable association with CKD in the 
screened population. Even when primary care physicians 
attempt targeted screening, data suggest that they may 
miss components (eg, urine testing) or fail to refer based 
on a modest rise in serum creatinine.31 32
In low-resource settings, where patients do not have 
opportunities for consistent primary care interactions, 
the likelihood that a person with asymptomatic CKD is 
referred for testing on the basis of comorbidities or an 
incidentally drawn serum creatinine is substantially lower 
than in higher resource settings. Thus, a formal strategy 
to identify persons at risk for CKD may have high clinical 
value. There is recent momentum to task-shift to commu-
nity health workers tooled with point-of-care screening 
strategies.33 In India, the government has developed an 
operational guideline for community health worker-facil-
itated screening for hypertension, diabetes and common 
cancers.34 Using this CKD screening strategy within such 
a context, in an Indian population where about 11% 
of persons have evidence of CKD on single time point 
testing and the cost of the more sensitive urine ACR 
testing is roughly 10-times the cost of a urine dipstick, 
our approach would have 60% lower screening costs 
than population-wide screening (out of 100 people, 35 
would be required to obtain further blood and urine 
testing). Successful implementation of such an approach 
could identify a vast majority (90%) of patients at high 
risk for progression (ie, those with albuminuria and 
eGFR <60 mL/min/1.73 m2, classified as stage 3A2 or 
above)16 35 in a resource-limited setting where treat-
ment for end-stage kidney disease is scarce and costly.2 
Emerging treatments, such as sodium-glucose co-trans-
porter 2 inhibitors, that potentially reduce the risk of 
progression of diabetic and non-diabetic CKD beyond 
that achieved by ACE inhibitors could further magnify 
the benefit for earlier CKD detection in LMICs.36 37
Though approaches to CKD screening have been 
studied in high-income settings,38 data from LMICs is 
sparse. Thakkinstian et al evaluated a strategy similar to 
ours in Thailand;13 they used community-based, cross-sec-
tional data to develop a prediction score for presence 
of CKD from a pool of laboratory and physical exam 
measurements as well as self-reported medical history 
and medication use. Their final model included four 
predictors (age, diabetes, hypertension and self-reported 
history of kidney stones) and performed well inter-
nally (validated c-statistic 0.74) and in a South African 
cohort.39 Although our proposed model involves seven 
components rather than four, it does not require a medi-
cation review or a fasting serum glucose test to identify 
presence of diabetes, the latter of which can increase 
cost and complicate logistics. Other prediction models 
for prevalent or incidence CKD have been performed in 
high-income settings38 and have often required serum 
fasting glucose to define diabetes and/or travel to a 
clinic for assessment.40 41 Further, some of these studies 
restricted the definition of CKD to an eGFR of <60 mL/
min/1.73 m2 and failed to include albuminuria,38 which 
is a sign of risk for progressive disease.42
Our model had slightly lower discrimination in the 
rural setting. Experts hypothesise that CKD in persons 
from rural areas may be more likely associated with 
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non-traditional risk factors, such as occult infection or 
environmental exposures.43 We tested a roster of avail-
able non-traditional factors, including occupation as 
an unskilled labourer, water source and cooking fuel 
(as a measure of household air pollution); none added 
substantially to model discrimination. Our model also 
had lower sensitivity in younger age groups and in those 
with a kidney stone compared with persons with diabetes 
or hypertension. However, the false negative rate was 
25% or lower for high-risk16 35 CKD across all strata.
Our study has additional limitations. We defined CKD 
using data from a single time point rather than repeated 
measures, which are recommended by expert groups to 
establish a CKD diagnosis.16 We do not have informa-
tion on some non-traditional risk factors for CKD such 
as recurrent or chronic infection and low birth weight, 
although self-report of these purported risk factors is 
unlikely to be accurate. Last, we do not yet have outcome 
data to allow us to determine the long-term cost-effective-
ness and health effects of our approach.
Nonetheless, our proposed region-specific model for 
India has acceptable discrimination and calibration, 
and unlike a majority of published studies,38 has been 
validated externally in an urban and rural setting using 
standardised and validated laboratory assays and data 
gathered at home visits using consistent protocols. We 
performed sensitivity analyses using alternate statistical 
methods and found consistent results. We selected our 
variable pool from large-scale population-based surveys 
that sought to capture sociodemographic non-communi-
cable risk factors specific to the Indian population. Our 
strategy is straightforward, requires a limited number of 
measurements and does not necessitate a formal clini-
cian visit for initial evaluation. As opposed to indiscrim-
inate screening strategies, our two-step approach could 
potentially reduce healthcare system costs, including 
those associated with infrastructural needs.
In summary, we built a simple point-of-care screening 
strategy for likelihood of CKD in urban India, one that 
could be rapidly integrated into community health 
worker visits and enable accurate and earlier detection 
of CKD.
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